Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor

We compared the outcomes of immunosuppressive treatment (IST) with those of alternative donor hematopoietic stem cell transplantation (HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 42 patients with SAA who received frontline IST ( N =19) or frontline HSC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2017-01, Vol.52 (1), p.47-52
Hauptverfasser: Choi, Y B, Yi, E S, Lee, J W, Sung, K W, Koo, H H, Yoo, K H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 52
container_issue 1
container_start_page 47
container_title Bone marrow transplantation (Basingstoke)
container_volume 52
creator Choi, Y B
Yi, E S
Lee, J W
Sung, K W
Koo, H H
Yoo, K H
description We compared the outcomes of immunosuppressive treatment (IST) with those of alternative donor hematopoietic stem cell transplantation (HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 42 patients with SAA who received frontline IST ( N =19) or frontline HSCT with an alternative donor ( N =23) between 1998 and 2012 were analyzed retrospectively. Six patients responded in the frontline IST group, whereas 11 underwent salvage HSCT after IST failure. Twenty-one of 23 patients who underwent frontline HSCT survived without treatment failure. The estimated failure-free survival rate of the frontline HSCT group was higher than that of the frontline IST group (91.3% vs 30.7% respectively, P
doi_str_mv 10.1038/bmt.2016.223
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859476851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A476578563</galeid><sourcerecordid>A476578563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-a53aa4f56f43ce03fb6484f2abc991665e8ffbed9db2f931eef82eb5c7e2ecdf3</originalsourceid><addsrcrecordid>eNqNksFu1DAQhiMEokvhxhlZQqo4kCWxY29yXFXQVlqJC5wjxxk3Lo4dbKdVX4mnZKK0VYt6QFEUOfPNP56ZP8vel8W2LFj9pRvTlhal2FLKXmSbstqJnDPBX2abgoo6Z0w0R9mbGK-Koqyqgr_OjuhOiBrfTfbnYhxn5-M8TQFiNNdA0gBBTrfkGkKcI5E2QXAyLaHeOx_IAKNMfvIGklEkJhiJAmtJCtLFyUqXkPaOaGTVYGwfwJEbkwYSAUWBSITikisdjEaSm8ETK9UvPJPzwz5HeTVAT7QcjTXSrnXfZq-0tBHe3X2Ps5_fvv44Pc8P388uTveHXHEqUi45k7LSXOiKKSiY7kRVV5rKTjVNKQSHWusO-qbvqG5YCaBrCh1XO6Cges2Os0-r7hT87xliakcTlwbxtn6ObVnzBodc8_J_UM4olq0Q_fgPeuVnnKtdqYLzCtf5QF1KC61x2uNQ1SLa7rEm39VcMKS2z1D49DhO5R1og_-fJJw8ShgAdzpEb-dlTfEp-HkFVfAxBtDtFMwow21bFu1itxbt1i52a9FuiH-4a2ruRugf4Ht_IZCvQMSQu4TwqOvnBP8CsrLiag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1855055410</pqid></control><display><type>article</type><title>Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Choi, Y B ; Yi, E S ; Lee, J W ; Sung, K W ; Koo, H H ; Yoo, K H</creator><creatorcontrib>Choi, Y B ; Yi, E S ; Lee, J W ; Sung, K W ; Koo, H H ; Yoo, K H</creatorcontrib><description>We compared the outcomes of immunosuppressive treatment (IST) with those of alternative donor hematopoietic stem cell transplantation (HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 42 patients with SAA who received frontline IST ( N =19) or frontline HSCT with an alternative donor ( N =23) between 1998 and 2012 were analyzed retrospectively. Six patients responded in the frontline IST group, whereas 11 underwent salvage HSCT after IST failure. Twenty-one of 23 patients who underwent frontline HSCT survived without treatment failure. The estimated failure-free survival rate of the frontline HSCT group was higher than that of the frontline IST group (91.3% vs 30.7% respectively, P &lt;0.001). Six of 11 patients who underwent salvage HSCT experienced event-free survival (EFS). The estimated EFS of the frontline HSCT group was higher than that of the salvage HSCT group (91.3% vs 50.9% respectively, P =0.015). The outcome of alternative donor HSCT was better than commonly reported rates, especially in patients who underwent frontline HSCT. These results suggest that frontline alternative donor HSCT may be a better treatment option than IST for children and adolescents with SAA who lack a human leukocyte Ag-matched familial donor.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2016.223</identifier><identifier>PMID: 27668766</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/100 ; 631/532 ; 692/699 ; Adolescent ; Age Factors ; Allografts ; Analysis ; Anemia, Aplastic - mortality ; Anemia, Aplastic - therapy ; Aplastic anemia ; Bone marrow ; Care and treatment ; Cell Biology ; Child ; Child health ; Child, Preschool ; Comparative analysis ; Disease-Free Survival ; Female ; Hematology ; Hematopoietic Stem Cell Transplantation ; HLA Antigens ; Humans ; Immunosuppression ; Infant ; Internal Medicine ; Male ; Medicine ; Medicine &amp; Public Health ; original-article ; Public Health ; Stem cell transplantation ; Stem Cells ; Survival Rate ; Unrelated Donors</subject><ispartof>Bone marrow transplantation (Basingstoke), 2017-01, Vol.52 (1), p.47-52</ispartof><rights>Macmillan Publishers Limited, part of Springer Nature. 2017</rights><rights>COPYRIGHT 2017 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-a53aa4f56f43ce03fb6484f2abc991665e8ffbed9db2f931eef82eb5c7e2ecdf3</citedby><cites>FETCH-LOGICAL-c526t-a53aa4f56f43ce03fb6484f2abc991665e8ffbed9db2f931eef82eb5c7e2ecdf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27668766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Y B</creatorcontrib><creatorcontrib>Yi, E S</creatorcontrib><creatorcontrib>Lee, J W</creatorcontrib><creatorcontrib>Sung, K W</creatorcontrib><creatorcontrib>Koo, H H</creatorcontrib><creatorcontrib>Yoo, K H</creatorcontrib><title>Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>We compared the outcomes of immunosuppressive treatment (IST) with those of alternative donor hematopoietic stem cell transplantation (HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 42 patients with SAA who received frontline IST ( N =19) or frontline HSCT with an alternative donor ( N =23) between 1998 and 2012 were analyzed retrospectively. Six patients responded in the frontline IST group, whereas 11 underwent salvage HSCT after IST failure. Twenty-one of 23 patients who underwent frontline HSCT survived without treatment failure. The estimated failure-free survival rate of the frontline HSCT group was higher than that of the frontline IST group (91.3% vs 30.7% respectively, P &lt;0.001). Six of 11 patients who underwent salvage HSCT experienced event-free survival (EFS). The estimated EFS of the frontline HSCT group was higher than that of the salvage HSCT group (91.3% vs 50.9% respectively, P =0.015). The outcome of alternative donor HSCT was better than commonly reported rates, especially in patients who underwent frontline HSCT. These results suggest that frontline alternative donor HSCT may be a better treatment option than IST for children and adolescents with SAA who lack a human leukocyte Ag-matched familial donor.</description><subject>13/100</subject><subject>631/532</subject><subject>692/699</subject><subject>Adolescent</subject><subject>Age Factors</subject><subject>Allografts</subject><subject>Analysis</subject><subject>Anemia, Aplastic - mortality</subject><subject>Anemia, Aplastic - therapy</subject><subject>Aplastic anemia</subject><subject>Bone marrow</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Child</subject><subject>Child health</subject><subject>Child, Preschool</subject><subject>Comparative analysis</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>HLA Antigens</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Infant</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>original-article</subject><subject>Public Health</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival Rate</subject><subject>Unrelated Donors</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNksFu1DAQhiMEokvhxhlZQqo4kCWxY29yXFXQVlqJC5wjxxk3Lo4dbKdVX4mnZKK0VYt6QFEUOfPNP56ZP8vel8W2LFj9pRvTlhal2FLKXmSbstqJnDPBX2abgoo6Z0w0R9mbGK-Koqyqgr_OjuhOiBrfTfbnYhxn5-M8TQFiNNdA0gBBTrfkGkKcI5E2QXAyLaHeOx_IAKNMfvIGklEkJhiJAmtJCtLFyUqXkPaOaGTVYGwfwJEbkwYSAUWBSITikisdjEaSm8ETK9UvPJPzwz5HeTVAT7QcjTXSrnXfZq-0tBHe3X2Ps5_fvv44Pc8P388uTveHXHEqUi45k7LSXOiKKSiY7kRVV5rKTjVNKQSHWusO-qbvqG5YCaBrCh1XO6Cges2Os0-r7hT87xliakcTlwbxtn6ObVnzBodc8_J_UM4olq0Q_fgPeuVnnKtdqYLzCtf5QF1KC61x2uNQ1SLa7rEm39VcMKS2z1D49DhO5R1og_-fJJw8ShgAdzpEb-dlTfEp-HkFVfAxBtDtFMwow21bFu1itxbt1i52a9FuiH-4a2ruRugf4Ht_IZCvQMSQu4TwqOvnBP8CsrLiag</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Choi, Y B</creator><creator>Yi, E S</creator><creator>Lee, J W</creator><creator>Sung, K W</creator><creator>Koo, H H</creator><creator>Yoo, K H</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170101</creationdate><title>Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor</title><author>Choi, Y B ; Yi, E S ; Lee, J W ; Sung, K W ; Koo, H H ; Yoo, K H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-a53aa4f56f43ce03fb6484f2abc991665e8ffbed9db2f931eef82eb5c7e2ecdf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>13/100</topic><topic>631/532</topic><topic>692/699</topic><topic>Adolescent</topic><topic>Age Factors</topic><topic>Allografts</topic><topic>Analysis</topic><topic>Anemia, Aplastic - mortality</topic><topic>Anemia, Aplastic - therapy</topic><topic>Aplastic anemia</topic><topic>Bone marrow</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Child</topic><topic>Child health</topic><topic>Child, Preschool</topic><topic>Comparative analysis</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>HLA Antigens</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Infant</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>original-article</topic><topic>Public Health</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival Rate</topic><topic>Unrelated Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Y B</creatorcontrib><creatorcontrib>Yi, E S</creatorcontrib><creatorcontrib>Lee, J W</creatorcontrib><creatorcontrib>Sung, K W</creatorcontrib><creatorcontrib>Koo, H H</creatorcontrib><creatorcontrib>Yoo, K H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Y B</au><au>Yi, E S</au><au>Lee, J W</au><au>Sung, K W</au><au>Koo, H H</au><au>Yoo, K H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>52</volume><issue>1</issue><spage>47</spage><epage>52</epage><pages>47-52</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>We compared the outcomes of immunosuppressive treatment (IST) with those of alternative donor hematopoietic stem cell transplantation (HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 42 patients with SAA who received frontline IST ( N =19) or frontline HSCT with an alternative donor ( N =23) between 1998 and 2012 were analyzed retrospectively. Six patients responded in the frontline IST group, whereas 11 underwent salvage HSCT after IST failure. Twenty-one of 23 patients who underwent frontline HSCT survived without treatment failure. The estimated failure-free survival rate of the frontline HSCT group was higher than that of the frontline IST group (91.3% vs 30.7% respectively, P &lt;0.001). Six of 11 patients who underwent salvage HSCT experienced event-free survival (EFS). The estimated EFS of the frontline HSCT group was higher than that of the salvage HSCT group (91.3% vs 50.9% respectively, P =0.015). The outcome of alternative donor HSCT was better than commonly reported rates, especially in patients who underwent frontline HSCT. These results suggest that frontline alternative donor HSCT may be a better treatment option than IST for children and adolescents with SAA who lack a human leukocyte Ag-matched familial donor.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27668766</pmid><doi>10.1038/bmt.2016.223</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0268-3369
ispartof Bone marrow transplantation (Basingstoke), 2017-01, Vol.52 (1), p.47-52
issn 0268-3369
1476-5365
language eng
recordid cdi_proquest_miscellaneous_1859476851
source MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects 13/100
631/532
692/699
Adolescent
Age Factors
Allografts
Analysis
Anemia, Aplastic - mortality
Anemia, Aplastic - therapy
Aplastic anemia
Bone marrow
Care and treatment
Cell Biology
Child
Child health
Child, Preschool
Comparative analysis
Disease-Free Survival
Female
Hematology
Hematopoietic Stem Cell Transplantation
HLA Antigens
Humans
Immunosuppression
Infant
Internal Medicine
Male
Medicine
Medicine & Public Health
original-article
Public Health
Stem cell transplantation
Stem Cells
Survival Rate
Unrelated Donors
title Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T23%3A38%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunosuppressive%20therapy%20versus%20alternative%20donor%20hematopoietic%20stem%20cell%20transplantation%20for%20children%20with%20severe%20aplastic%20anemia%20who%20lack%20an%20HLA-matched%20familial%20donor&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Choi,%20Y%20B&rft.date=2017-01-01&rft.volume=52&rft.issue=1&rft.spage=47&rft.epage=52&rft.pages=47-52&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2016.223&rft_dat=%3Cgale_proqu%3EA476578563%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1855055410&rft_id=info:pmid/27668766&rft_galeid=A476578563&rfr_iscdi=true